XTalks

JULY 19, 2022

The two-dose protein-based, adjuvanted vaccine has been authorized for use in adults 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. In a press release outlining the authorization, the FDA noted that the clinical trial for Novavax’s vaccine was conducted before the appearance of the omicron and delta variants.

Vaccination 94

Vaccination Vaccine Protein Clinical Trials 94

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

MARCH 30, 2021

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio.

Protein 52

Protein Licensing Licensing Containment 52

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

SEPTEMBER 22, 2022

AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Cystinosis patients have a high deficiency of this protein.

Gene Therapy 147

Gene Therapy Gene Protein Licensing 147

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Drugs Development 52

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. According to pre-clinical findings, a booster dose of this vaccine elicited a robust neutralising antibody response against the variants Omicron BA.1,

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

XTalks

FEBRUARY 19, 2024

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. However, the development of an effective vaccine that can target CMV infection has been extremely challenging.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

MARCH 6, 2024

This second ODD allows research and development of a therapy for another form of the disease, Isolated Hypomyelination. Our whole strategy is centred around achieving these prestigious designations, which make development of therapeutics easier and more cost-effective.”

Drugs 52

Drugs Protein Gene Licensing 52

The Pharma Data

JANUARY 3, 2021

. United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application. With these important regulatory clearances for our first-in-human clinical trial for INZ-701 in subjects with ENPP1 deficiency, we have transitioned from a research-stage to a clinical-stage company.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. It has licensed in a patented breathalyser, the analysts noted. A large clinical trial is ongoing in Dubai.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

Drug Discovery World

NOVEMBER 14, 2023

What is particularly noteworthy when it comes to the mAbs being developed and approved for Covid-19 is drug repurposing, showing the scope of future treatments with mAbs. A prime example of repurposing for rare disease is Eculizumab, which targets the C5 protein.

Antibody 59

Antibody Development FDA Approval Trials 59

Delveinsight

JANUARY 12, 2021

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant. Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. BeiGene, Novartis partner to develop cancer drug Tislelizumab, an Anti-PD-1 Antibody.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. In both trials, approximately 38 percent of the screened patients had CLDN18.2-positive

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.

Antibody 92

Antibody Drugs Protein Licensing 92

The Pharma Data

DECEMBER 13, 2020

Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. “RLY-1971 To learn more about the first-in-human clinical trial of RLY-1971, please visit here.

Licensing 40

Licensing Licensing Sales Clinical Trials 40

The Pharma Data

APRIL 12, 2023

Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ). We are pleased with Biogen’s decision to license ATV: Aβ and we are hopeful this will foster the development of next-generation anti- Aβ therapeutics.”

Antibody 40

Antibody Development Engineer Licensing 40

The Pharma Data

APRIL 29, 2022

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant, to the Korean Ministry of Food and Drug Safety (KMFDS) following positive Phase III clinical data.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology. Transaction Terms.

Vaccination 52

Vaccination Vaccine Development Licensing 52

Drug Discovery World

APRIL 5, 2023

The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, London. It targets a pathway that cancer cells are highly dependent upon, involving the heat shock factor 1 protein (HSF1).

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

The Pharma Data

NOVEMBER 29, 2020

It has high expression in tumors and plays a key role in the occurrence and development of tumors. Binding to the MDM2 protein with high affinity, MDM2 inhibitor blocks the MDM2-p53 interactions and restore the tumor-suppressing activity of p53. We look forward to the further development of the asset by Ascentage Pharma.”

Licensing 40

Licensing Licensing Protein Drugs 40

pharmaphorum

JUNE 17, 2021

Tau is a protein that is found in cells of the central nervous system and is involved in the assembly and stabilisation of neuronal microtubules – channels used to transport substances to different parts of the nerve cell. In Alzheimer’s, the protein runs amok, forming tangles that have been linked to cell damage and neuronal death.

Antibody 98

Antibody Protein Licensing Licensing 98

pharmaphorum

APRIL 8, 2022

billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. As it is in the very early stages Jazz’s licensing deal is heavily back-weighted, but does include $1.26 billion in development, regulatory and commercial milestones. Image by Lukas Bieri from Pixabay .

Drugs 98

Drugs Immune Response Licensing Licensing 98

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth. Chiesi and Oak Hill Bio intend to continue a Phase IIb clinical trial in 2024 in the United States, Europe, and Japan.

Drugs 59

Drugs Licensing Licensing Protein 59

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. While the exact causes of ALS are not fully understood, research suggests that the mutation of SOD1 may be linked to the development of the condition. What is SOD1 -ALS?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

pharmaphorum

FEBRUARY 4, 2022

It is being manufactured at a facility in Teesside owned by FUJIFILM Diosynth Biotechnologies, although a report in The Times suggests that any initial supplies will be imported from India, where it is made under license by Serum Institute. It was also filed in the US earlier this month after development and manufacturing setbacks.

Vaccination 97

Vaccination Vaccine Protein Manufacturing 97

XTalks

FEBRUARY 20, 2024

Sibeprenlimab marks the first among a series of precision therapy biologics developed by Visterra to address the substantial unmet medical needs of chronic kidney disease patients. Consequently, this damage causes blood and protein leakage into the urine. At month 12, the percentage of patients achieving clinical remission was 7.9

Clinical Trials 59

Clinical Trials Clinical Trials FDA Approval Trials 59

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Licensing 40

Licensing Licensing Production Development 40

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Could you discuss the TCR T-cell target MAGE-A4 and what discoveries could be made by targeting this protein?

Antibody 64

Antibody Protein Development Engineer 64

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52